Cytomegalovirus peptide vaccine (PepVax) - Helocyte

Drug Profile

Cytomegalovirus peptide vaccine (PepVax) - Helocyte

Alternative Names: CMV fusion peptide vaccines - Helocyte; CMVPepVax; CMVpp65-A*0201 peptide vaccine - Helocyte; Tet-CMV

Latest Information Update: 20 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator City of Hope National Medical Center
  • Developer City of Hope National Medical Center; National Cancer Institute (USA); University of Minnesota
  • Class Cytomegalovirus vaccines; Immunotherapies; Peptide vaccines; Recombinant fusion proteins; T lymphocyte cell therapies; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cytomegalovirus infections

Most Recent Events

  • 04 May 2015 City of Hope and National Cancer Institute plans a phase II trial in Cytomegalovirus infections (Prevention, in HLA A*0201 cytomegalovirus-seropositive with haematological malignancies undergoing donor stem cell transplant) in USA (SC) (NCT02396134; 9178335)
  • 01 May 2015 Phase-II clinical trials in Cytomegalovirus infections (Prevention) in USA (SC) (NCT02396134)
  • 02 Apr 2015 Cytomegalovirus peptide vaccine (PepVax) licensed to DiaVax Biosciences worldwide for the treatment/prevention of Cytomegalovirus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top